

Addendum

Addendum: Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report**Hongqing Zhuang^{1,*}, Xiangkun Yuan^{2,*}, Dayong Sun³, Jianliang Bian⁴, Joe Y. Chang⁵, Zhiyong Yuan¹ and Ping Wang¹**

¹Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

²Department of Radiotherapy, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Hebei, China

³Department of Chemo-Radiotherapy, Chengde Center Hospital, Second Clinical Medical School of Chengde Medical University, Hebei, China

⁴Department of Radiotherapy, Affiliated Hospital of Hebei University, Hebei, China

⁵Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

*These authors have contributed equally to this work

Published:

Copyright: © 2023 Zhuang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was required and obtained.

Original article: Oncotarget. 2016; 7:13265–13268. <https://doi.org/10.18632/oncotarget.7724>